Latest news with #ROS
Barnama
22-07-2025
- Politics
- Barnama
New Youth Age Limit: Leaders Over 30 May Hold Posts Until Next Election
KUALA LUMPUR, July 22 (Bernama) -- Youth leaders who exceed the age of 30 after the youth age limit takes effect on Jan 1, 2026 may continue to hold their positions until their organisation's next election at the general meeting, said Youth and Sports Minister Hannah Yeoh. However, Hannah said these leaders cannot be renominated, as stipulated under Section 6 of the Youth Societies and Youth Development (Amendment) Act 2019 (Act A1602). 'For youth members, starting from Jan 1, 2026, in line with the amendment to Act 668 through Act A1602, ordinary members who do not hold office in youth organisations and have reached or exceeded the age of 30 will no longer be eligible as ordinary members. They will also lose their right to vote or be elected at annual general meetings. 'However, they can still be involved as advisors, mentors, facilitators, mobilisers, youth workers, or alumni, subject to the organisation's constitution. In this regard, the Ministry of Youth and Sports (KBS) has engaged with the Registrar of Societies (ROS) to facilitate the transition for youth organisations, office bearers, or members who reach the age of 30 to join other associations registered under ROS,' she said during a question-and-answer session in the Dewan Rakyat today. She was responding to a supplementary question from Dr Kelvin Yii (PH-Bandar Kuching), who asked what would happen if youth leaders exceeded the age of 30 after the law comes into force on Jan 1, 2026. In response to Yii's original question, Hannah said KBS has taken several initiatives to ease the transition of the youth age limit from 40 to 30 years old. She said these include the formation of a Transition Working Committee chaired by Deputy Youth and Sports Minister Adam Adli Abdul Halim, the implementation of Bicara Transisi Belia (Youth Transition Dialogues), Governance Workshops, Organisational Management Programmes (PPO), the Kembara Jumpa Orang Muda Programme (Kembara JOM) and the certification of youth work professionalism. According to her, the Department of Statistics Malaysia data shows there are 9.5 million youths aged 15 to 30, making up 27.9 per cent of the national population, while the number of office bearers in youth organisations this year stands at 99,271, with 53.99 per cent (or 53,606 individuals) under the age of 30. 'The enforcement of the Youth Societies and Youth Development (Amendment) Act 2019 will affect the administration and leadership of 8,272 youth organisations registered with the Registrar of Youth Societies (ROY),' she said.
Business Wire
09-07-2025
- Health
- Business Wire
Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. Bonerge's 12-week, quadruple-blind study evaluates how Urolithin A and Fisetin influence sleep via metabolic and epigenetic biomarkers. Share This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combination, and placebo control. The 12-week intervention represents the first systematic evaluation of Urolithin A's potential to resynchronize circadian rhythms and mitigate age-related sleep disturbances. Key Study Design Features: Inclusion Criteria: Targets subclinical individuals with impaired sleep quality (PSQI score >5) but no pathological diagnosis, excluding those dependent on caffeine/alcohol. Multidimensional Assessment: Subjective: Sleep quality scores, chronotype questionnaire, daytime dysfunction scales. Objective: Continuous actigraphy monitoring, polysomnography (PSG) analysis. Biomarkers: NAD+ levels, DNA methylation age, inflammatory markers (IL-6, TNF-α), cortisol rhythm, circadian proteins (BMAL1, PER2), insulin resistance (HOMA-IR), immunoglobulin levels. "We aim to uncover the causal link between sleep disorders and ageing using epigenetic clocks and metabolic markers, beyond just tracking sleep duration," stated Professor Chen, the lead investigator. "Combining Urolithin A, a circadian regulator, with the senolytic Fisetin explores synergy for novel solutions, like menopausal sleep issues." Scientific Commitment: Building a Health Ecosystem As a leading high-quality ingredient producer, Bonerge's R&D follows a pipeline of 'ingredient science, mechanistic research, clinical translation'. The company is actively seeking global clinical partners from academia and industry to explore Urolithin A's potential in sleep health and cellular ageing intervention. Amidst the anti-ageing industry's shift from consumerism to scientific rigor, Bonerge positions Urolithin A not just as a standalone ingredient, but as a catalyst for evidence-based solutions. Focused on core mechanisms like cellular senescence, Bonerge develops innovative ingredients targeting cellular health, forming a robust "health ecosystem." Key components include: Fisetin: Potent senolytic selectively clearing senescent cells and reducing their formation, retarding aging in skin, ovarian, and neural tissues. Urolithin A: Regulates circadian rhythms, boosts endogenous NAD+ synthesis, enhances cellular repair, and improves sleep quality and reproductive health. L-Ergothioneine: Unique antioxidant with a dedicated transporter (OCTN1), accumulating in high-stress tissues to neutralize ROS, protecting DNA and telomeres. PQQ Disodium: Activates the PGC-1α/PPARγ pathway, driving mitochondrial DNA replication and biogenesis. S - Equol: Natural, non-steroidal estrogenic metabolite with high affinity for ERβ, offering a safer alternative for menopause health. About Bonerge Bonerge firmly contends that the future of anti-ageing hinges on evidence-based solutions. These solutions are grounded in well-defined biological mechanisms, supported by robust scientific data, and tailored to precise applications, ultimately delivering comprehensive, science-validated health benefits. For more detailed information about our clinical findings, discover more about us at
Mid East Info
08-07-2025
- Science
- Mid East Info
RIT Dubai study shows improvement in academic performance with integration of AI and robotics - Middle East Business News and Information
Research demonstrates positive impact of personalized robotic tutoring in elementary education A study conducted by researchers from Rochester Institute of Technology (RIT) of Dubai has revealed the positive impact of integrating artificial intelligence (AI) and robotics into education at elementary school level. The groundbreaking project used a personalized AI-powered robot to interact with students directly, resulting in an average 8% improvement in academic performance, versus outcomes from human teaching. Led by Dr. Jinane Mounsef, Chair of the university's Electrical Engineering and Computing Sciences Department, the research highlighted the potential of personalization in robotic tutoring in a real-world educational setting. Combining cognitive and emotional assessment to deliver tailored educational experiences, the tutoring system was tested with a group of grade four school students studying mathematics. In addition to measuring the speed and accuracy of a student's performance, the robot conducted real-time facial expression analysis to determine the learner's state of mind. The metrics were combined to classify students into three categories: Proficient Students (Prof.S), Meeting-Expectations Students (MES), and Developing Students (DVS). These classifications were then used to deliver customized learning content, motivational messages, and constructive feedback to the students. The robot, known as Duet, employed powerful machine learning algorithms and the ROS framework to predict a student's proficiency level with 100% accuracy through indicators such as test scores, task completion time, and emotional engagement. It was then able to adjust the challenges and learning materials dynamically to suit each student's needs. The process also incorporated feedback mechanisms for participants to share their thoughts on the experience of learning through robotics and AI. Explaining the rationale and findings of the research, Dr. Mounsef said, 'We wanted to explore whether personalization enhances the effectiveness of a robotic tutor in improving learning outcomes. To do this, we considered how engagement and academic performance were impacted by the personalization of robotic tutoring and how the results compared to a human teacher, which serves as a benchmark for evaluating the system's impact. Through post-diagnostic exams we found that the experimental group of students using the AI-robot system showed a significant improvement rate over the control group. This demonstrates that such systems can provide a powerful tool to improve efficiency and augment education outcomes.' The research was the subject of an academic paper entitled, 'CARE: towards customized assistive robot-based education', authored by Dr. Mounsef, alongside RIT Dubai graduate student, Nafisa Maaz, and Assistant Professor at Lebanese American University Beirut, Dr. Noel Maalouf. The paper was published by Frontiers in Robotics and AI, a world-leading, multidisciplinary scientific journal. Building on the project, Dr. Mounsef is now preparing to collaborate with colleagues at RIT New York to develop an AI-powered social robot. She concluded, 'We aim to take forward our work in cognitive development to explore the use of robotics in emotional intelligence. This will involve deploying a human-looking robot that can interact with students on a daily basis to ask questions, gather data and ultimately make recommendations that can help to address their concerns.' About RIT Dubai Established in 2008, RIT Dubai is a not-for-profit global campus of the esteemed Rochester Institute of Technology in New York, one of the world's leading technological-focused universities with more than 185 years of history. RIT Dubai is now operating from phase one of its new $136 million state-of-the-art campus which provides interactive learning space set over 129,000 square meters. RIT Dubai offers highly valued Bachelor's and Master's degrees in business, psychology, media design, leadership, engineering, and computing. The curriculum provides students with relevant work experience through an innovative cooperative education program that helps students stand out in today's highly competitive job market. RIT Dubai offers American degrees issued directly from the main campus in New York, and all of RIT's programs are UAE Ministry accredited. Students of RIT Dubai also have the unique opportunity to choose to study abroad at the main campus in New York or at one of its other global campuses.
Business Wire
26-06-2025
- Business
- Business Wire
Sensus Healthcare Engages Radiology Oncology Systems (ROS) as Primary Distribution Partner for its SRT Systems to Radiation Oncologists
BUSINESS WIRE)-- Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it has entered into a strategic agreement with Radiology Oncology Systems (ROS) to serve as the Company's primary distribution partner for the U.S. radiation oncology market. Under the terms of the agreement, ROS will be responsible for selling Sensus's superficial radiotherapy (SRT) systems, including the SRT-100™ and the SRT-100 Vision™, to hospital-based radiation oncology departments and freestanding oncology centers nationwide. Led by President and CEO John Vano, ROS brings nearly three decades of experience and deep-rooted relationships across radiation oncology, including familiarity with the SRT machines. This new partnership will leverage ROS's extensive presence across all 50 states to accelerate adoption of Sensus's image-guided, non-invasive radiotherapy technologies within the oncology continuum of care. Initial orders under the agreement are expected as early as the fourth quarter of 2025, with the potential to expand the distribution agreement to select international markets in the future. 'The benefits of our SRT systems are increasingly being recognized by largely untapped markets outside our core focus on dermatology, and we're excited to partner with ROS as we deepen our penetration into the hospital-based oncology market,' said Joe Sardano, Chairman and CEO of Sensus Healthcare. 'John and his team have an excellent reputation for delivering value and reliability to radiation oncology departments and clinics. We believe this collaboration will meaningfully accelerate the placement of SRT systems into cancer centers that are seeking non-invasive solutions with excellent aesthetic outcomes and minimal disruption to clinical workflows.' 'Sensus's SRT platform represents an important and growing modality within radiation oncology. By integrating these systems into hospital settings and outpatient oncology centers, we can help providers offer more flexible treatment options while enhancing overall workflow efficiency, patient access and customer satisfaction. We're proud to bring our commercial infrastructure to this partnership and look forward to working closely with the Sensus team to bring SRT to more oncology practices across the country,' commented Mr. Vano. This partnership marks another step in Sensus's strategy to expand beyond dermatology and into hospital and multidisciplinary oncology environments. The Company continues to invest in commercialization and reimbursement initiatives to support broader adoption of its superficial radiation technologies across priority markets. About Sensus Healthcare Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit Forward-Looking Statements This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," 'approximately,' "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company's information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Time of India
07-06-2025
- Science
- Time of India
Russia patents drone tech: Orbital station to launch spacecraft automatically; robots to maintain station
Russia patents space technology, uses robots for maintenance of orbital stations (Representative image: PTI) Russia has developed and patented a new technology that allows spacecraft to be launched automatically from an orbital station, Russian news agency TASS reported. This system also includes robotic maintenance features, making it the first of its kind in the world. The technology will be tested at the upcoming Russian Orbital Station (ROS), and later used in future lunar exploration missions . Russia's first deputy Prime Minister Denis Manturov informed President Vladimir Putin about the developments of this technology, emphasising at Russia's need to transition to its own orbital station, module-by-module by 2030. The ROS 'will become the world's first drone platform equipped with robots for its maintenance. This is a patented solution of the Russian Federation,' Manturov said during the meeting on Friday, as reported by PTI. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo The meeting was chaired by Putin through a televised medium to assess the current national projects, particularly in the field of space. Work is currently underway to develop the Russian Orbital Station (ROS), which is planned for deployment in a near-polar orbit between 2027 and 2033. The scientific and power module (SPM), representing the first segment of the ROS, is scheduled for launch at the end of 2027. By 2030, additional components including the universal-node, gateway, and base modules are planned for launch, which together with the SPM will form the station's core infrastructure. The second phase of the station's deployment will involve expanding the facility by docking two target modules between 2031 and 2033. The deployment of Russia's orbital station is expected to begin after the scheduled deorbiting of the International Space Station by 2030. This transition comes after valuable joint space collaboration experience between Roscosmos and Nasa.
